Skip to main content

Table 3 Response to trabectedin according to the line of treatment

From: Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

 

Best response to trabectedine

Total

   

NE

PD

SD

PR

Line of treatment

1

N

0

3

4

3

10

  

%

,0%

30,0%

34,0%

30,0%

100,0%

 

2

N

1

32

26

8

67

  

%

1,5%

47,8%

38,8%

11,9%

100,0%

 

3

N

4

26

27

3

60

  

%

6,7%

43,3%

45,0%

5,0%

100,0%

 

4

N

4

22

12

4

42

  

%

9,5%

52,4%

28,6%

9.5%

100,0%

Total

N

9

83

69

18

179

  

%

5,0%

46,4%

38,5%

10,1%

100,0%